Cernitol, a herbal pharmaceutical medicine to treat symptoms caused by benign prostate diseases. Has been more and more recognised in Sweden as an effective and safe alternative to use.
During the national conference in Gothenburg organized by the Swedish Association of Urology, AB Cernelle is awarded as Bronze sponsor.
Associate Professors Magnus Grabe and Hans Hedelin will lead a seminar about the role of inflammation i the prostate gland and whether this contribute to the development of Lower Urinary Tract Symptoms (LUTS) and chronic pelvic pain?
More information: Ken Tinebo, VD Cernelle, +46 730 877 637 email@example.com
About AB Cernelle: Cernelle is a Swedish pharmaceutical company with research and development of medicine in urology; chronic prostatitis/pelvic pain syndrome (CP/CPPS) and benign prostate enlargement (BPH). Cernelle has developed herbal pharmaceuticals from superior pollen extract since 1953. With over 50 million daily doses per year, Cernitol is one of the worlds most used medicine to treat benign prostate diseases.
The company have 35 employees at the facilities outside Ängelholm in Southern Sweden. To manage the ongoing expansion and growth it is expected to recruit 25-30 talented and skilled people within a three years period. Turnover is currently 7 million euro with a good earning and Cernelle is owned by Backahill AB since 2005.